Placebo every 2 weeks

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

Autoimmune DiseaseConnective Tissue DiseaseSystemic Lupus Erythematosus

Phase 3

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

CompletedNCT01196091

Eli Lilly and CompanyAutoimmune Disease, Connective Tissue Disease, Systemic Lupus Erythematosus

Start: 2010-12-31End: 2015-06-30Updated: 2018-06-12

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

CompletedNCT01205438

Eli Lilly and CompanyAutoimmune Disease, Connective Tissue Disease, Systemic Lupus Erythematosus

Start: 2011-01-31End: 2015-03-31Updated: 2018-07-17

Related Papers

XIST EXPRESSION IN MALES WITH SYSTEMIC LUPUS ERYTHEMATOSUS: BIMODAL DISTRIBUTION AND PARTIAL X-CHROMOSOME INACTIVATION

The Journal of Rheumatology2025-05-20

Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.

2018-01-0110 citations

The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials

Lupus2016-05-2529 citations

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

2015-09-03171 citations

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

2015-08-20163 citations